ROBICHAUD ALBERT (Chief Scientific Officer) received a stock award from SAGE THERAPEUTICS, INC.
Compensation award — not an open‑market transaction. Less informative as a directional signal.
A · 1 award
Filed: 2/7/2023ACC: 0001562180-23-001082
Officer· Chief Scientific Officer
Since Dec 2018
+2.25K
Net shares
Net buyer
$49.8K
Total sold
0
Open market trades
0B · 0S
2
Total transactions
3.38K acquired · 1.13K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+3.38K
Price / share
—
Trade value
—
% of position
2.4%
2/3/2023
143.31K→146.68K
Common Stock
Direct
Shares
−1.13K
Price / share
$44.16
Trade value
$49.77K
% of position
0.8%
2/3/2023
146.68K→145.55K
Total
Net shares
+2.25K
Net value
-$49.77K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 2/3/2023 | A · Award | +3.38K | — | — | 2.4% | 143.31K | 146.68K |
| Common Stock Direct | 2/3/2023 | F · Tax Withholding | −1.13K | $44.16 | $49.77K | 0.8% | 146.68K | 145.55K |
| Total | +2.25K | -$49.77K | ||||||
Derivative Transactions0
No derivative transactions reported